Interferons play important roles in defense mechanisms against viral infection, and thus interferon therapy has been a standard treatment in chronic hepatitis B patients. Interferons signaling pathways promote interferon-inducible genes including microRNAs. In this research, we aimed to determine microRNAs expression profiles in vitro and in vivo. For in vitro model, Huh7 cells were transfected with or without hepatitis B virus plasmid for 6 h, and then treated with 100 ng of pegylated-interferon alpha-2a for 24 h. In vivo, we defined microRNAs expression profiles in pair-liver tissues of chronic hepatitis B patients in comparison between before and after treatment of pegylated-interferon alpha-2a for 48 weeks. Cellular small RNAs were extracted followed by library preparation. To determine microRNAs expression profiles, the next-generation sequencing was carried out on MiSeq platform (Illumina®). In vitro analysis demonstrated that microRNAs can be classified into up-regulated and down-regulated microRNAs in response to hepatitis B virus, interferon, and combination of hepatitis B virus and interferon. Moreover, in vivo analysis revealed microRNAs profiles in non-responders, responders without hepatitis B surface antigen clearance, and responders with hepatitis B surface antigen clearance. The target genes of the candidate microRNAs were determined in terms of roles in cellular pathways and immune response, which might be related to treatment in chronic hepatitis B patients. Results revealed that two down-regulated microRNAs including miR-185-5p and miR-186-5p were correlated in both in vitro and in vivo studies. These two microRNAs might be represented as specific hepatic microRNAs responding to hepatitis B virus and pegylated-interferon alpha-2a treatment, which may remarkable and attractive for further study involving in the association of their target genes and prediction of pegylated-interferon alpha-2a response. Interestingly, microRNAs expression patterns might be useful for understanding the response mechanism and serve as biomarkers for prediction of pegylated-interferon alpha-2a treatment response in patients with chronic hepatitis B.
HagymasiKTulassayZ. Epidemiology, risk factors and molecular pathogenesis of primary liver cancer. Orv Hetil2008; 149: 541–8.
2.
El-SeragHBRudolphKL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology2007; 132: 2557–76.
3.
KewMC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris)2010; 58: 273–7.
4.
NeuveutCWeiYBuendiaMA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol2010; 52: 594–604.
5.
ZhangYWuYYeSWangTZhaoRChenFAbeKJinX. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo. Virus Res2013; 171: 65–70.
6.
PoynardTBedossaPChevallierMMathurinPLemonnierCTrepoCCouzigouPPayenJLSajusMCostaJM. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med1995; 332: 1457–62.
CooksleyWG. Do we need to determine viral genotype in treating chronic hepatitis B?J Viral Hepat2010; 17: 601–10.
9.
SleijferSBanninkMVan GoolARKruitWHStoterG. Side effects of interferon-alpha therapy. Pharm World Sci2005; 27: 423–31.
10.
LauGKPiratvisuthTLuoKXMarcellinPThongsawatSCooksleyGGaneEFriedMWChowWCPaikSWChangWYBergTFlisiakRMcCloudPPluckN. Peginterferon Alfa-2a H-PCHBSG. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med2005; 352: 2682–2695.
11.
JanssenHLvan ZonneveldMSenturkHZeuzemSAkarcaUSCakalogluYSimonCSoTMGerkenGde ManRANiestersHGZondervanPHansenBSchalmSWGroupHBVS. Rotterdam Foundation for Liver R. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet2005; 365: 123–9.
12.
RodriguezAGriffiths-JonesSAshurstJLBradleyA. Identification of mammalian microRNA host genes and transcription units. Genome Res2004; 14: 1902–10.
13.
LewisBPBurgeCBBartelDP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell2005; 120: 15–20.
14.
TangYLuoXCuiHNiXYuanMGuoYHuangXZhouHde VriesNTakPPChenSShenN. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum2009; 60: 1065–75.
15.
MitchellPSParkinRKKrohEMFritzBRWymanSKPogosova-AgadjanyanELPetersonANoteboomJO'BriantKCAllenALinDWUrbanNDrescherCWKnudsenBSStirewaltDLGentlemanRVessellaRLNelsonPSMartinDBTewariM. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA2008; 105: 10513–8.
16.
TerraultNABzowejNHChangKMHwangJPJonasMMMuradMH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology2016; 63: 261–83.
17.
SugiyamaMTanakaYKatoTOritoEItoKAcharyaSKGishRGKramvisAShimadaTIzumiNKaitoMMiyakawaYMizokamiM. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology2006; 44: 915–24.
18.
FrogerAHallJE. Transformation of plasmid DNA into E. coli using the heat shock method. J Vis Exp2007; 6: 253–253.
19.
RoglerCELevociLAderTMassimiATchaikovskayaTNorelRRoglerLE. MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. Hepatology2009; 50: 575–84.
20.
YuanBDongRShiDZhouYZhaoYMiaoMJiaoB. Down-regulation of miR-23b may contribute to activation of the TGF-beta1/Smad3 signalling pathway during the termination stage of liver regeneration. FEBS letters2011; 585: 927–34.
21.
SarverALLiLSubramanianS. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer research2010; 70: 9570–9580.
22.
LiJFuHXuCTieYXingRZhuJQinYSunZZhengX. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer2010; 10: 354–354.
23.
BelkayaSMurraySEEitsonJLde la MorenaMTFormanJAvan OersNS. Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1. J Biol Chem2013; 288: 30752–62.
24.
FlachHRosenbaumMDuchniewiczMKimSZhangSLCahalanMDMittlerGGrosschedlR. Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells. Immunity2010; 33: 723–35.
25.
GoeppertBSchmezerPDutruelCOakesCRennerMBreinigMWarthAVogelMNMittelbronnMMehrabiAGdyniaGPenzelRLongerichTBreuhahnKPopandaOPlassCSchirmacherPKernMA. Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology2010; 52: 2023–33.
26.
LiYBaiHZhangZLiWDongLWeiXMaYZhangJYuJSunGWangF. The up-regulation of miR-199b-5p in erythroid differentiation is associated with GATA-1 and NF-E2. Mol Cells2014; 37: 213–9.
27.
ZhangQYuanYCuiJXiaoTJiangD. MiR-217 Promotes tumor proliferation in breast cancer via targeting DACH1. J Cancer2015; 6: 184–91.
28.
ZhaoWGYuSNLuZHMaYHGuYMChenJ. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis2010; 31: 1726–33.
29.
Asghari AlashtiFMinuchehrZ. MiRNAs which target CD3 subunits could be potential biomarkers for cancers. PLoS One2013; 8: e78790–e78790.
30.
ChenBDuanLYinGTanJJiangX. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells – Cdc2 activity is up-regulated by targeting WEE1. Clinics2013; 68: 825–33.
31.
Shalom-FeuersteinRSerrorLDe La Forest DivonneSPetitIAberdamECamargoLDamourOVigourouxCSolomonAGaggioliCItskovitz-EldorJAhmadSAberdamD. Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specification. Stem cells2012; 30: 898–909.
32.
LiAQianJHeJZhangQZhaiASongWLiYLingHZhongZZhangF. Modulation of miR122 expression affects the interferon response in human hepatoma cells. Mol Med Rep2013; 7: 585–90.
33.
TnaniMBayardBA. Evidence for IRF-1-dependent gene expression deficiency in interferon unresponsive HepG2 cells. Biochim Biophys Acta1999; 1451: 59–72.
34.
DaiXZhangWZhangHSunSYuHGuoYKouZZhaoGDuLJiangSZhangJLiJZhouY. Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1alpha. Nucleic Acids Res2014; 42: 6578–90.
35.
ChengMSiYNiuYLiuXLiXZhaoJJinQYangW. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol2013; 87: 9707–18.
36.
WangKCGarmireLXYoungANguyenPTrinhASubramaniamSWangNShyyJYLiYSChienS. Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth. Proc Natl Acad Sci USA2010; 107: 3234–9.
37.
SalviASabelliCMonciniSVenturinMAriciBRivaPPortolaniNGiuliniSMDe PetroGBarlatiS. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J2009; 276: 2966–82.
38.
GoodwinDRosenzweigBZhangJXuLStewartSThompsonKRouseR. Evaluation of miR-216a and miR-217 as potential biomarkers of acute pancreatic injury in rats and mice. Biomarkers2014; 19: 517–29.
39.
BelverLde YebenesVGRamiroAR. MicroRNAs prevent the generation of autoreactive antibodies. Immunity2010; 33: 713–22.
40.
DangerRBrazaFGiralMSoulillouJPBrouardS. MicroRNAs, major players in B cells homeostasis and function. Front Immunol2014; 5: 98–98.
41.
ChoiMCJongHSKimTYSongSHLeeDSLeeJWKimTYKimNKBangYJ. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene2004; 23: 7095–103.
42.
FlothoCPaulunABatzCNiemeyerCM. AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies. Br J Haematol2007; 138: 644–50.
43.
NohJHChangYGKimMGJungKHKimJKBaeHJEunJWShenQKimSJKwonSHParkWSLeeJYNamSW. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer letters2013; 335: 455–62.
44.
CuiSYWangRChenLB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med2014; 18: 1913–26.
45.
XuNZhangJShenCLuoYXiaLXueFXiaQ. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun2012; 423: 826–31.
46.
ShenQCicinnatiVRZhangXIacobSWeberFSotiropoulosGCRadtkeALuMPaulAGerkenGBeckebaumS. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Molecular cancer2010; 9: 227–227.
47.
DavisMM. A new trigger for T cells. Cell2002; 110: 285–7.
